SecBot SecBot
PRESS-RELEASE ·Filed Apr 30, 2026

OPK

OPKO Health, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The amendment is a non-cash strategic alignment with no near-term revenue catalyst. Monitor for 2027 regulatory decisions in China and any subsequent milestone triggers. The equity stake provides optional upside but is highly speculative given Nicoya's private status and long timeline.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.13
T+0 close · Apr 30, 2026 · via day close
Latest settled
+9.73%
T+60 · $1.24
Vs SPY
+6.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $1.13entry
  2. T+1 · 7mo ago −2.65%α −2.87% · $1.10
  3. T+5 · 6mo ago −0.89%α −2.61% · $1.12
  4. T+20 · 6mo ago +26.55%α +21.58% · $1.43
  5. T+60 · 4mo ago +9.73%α +6.63% · $1.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in exchange for revised royalty/transfer pricing, while keeping the $115M milestone structure intact. The deal deepens strategic alignment for RAYALDEE commercialization in Greater China, where regulatory approvals are expected in 2027, but provides no immediate revenue or cash consideration.

Key Facts

  • OPKO received a 15% equity stake in Nicoya via Series A-2 Preferred Shares in two tranches.
  • Revised tiered royalty and transfer price schedule replaces prior terms; milestone payments up to $115M unchanged.
  • RAYALDEE approved in Macau; regulatory approvals in China and related territories expected in 2027.
  • No upfront cash payment or immediate revenue recognized from the amendment.
  • OPKO's market cap is ~$843M; the equity stake value and milestone potential are unquantified in the release.

Financial Impact

Equity stake of 15% in Nicoya (private, unvalued); milestone potential up to $115M but contingent on future regulatory/sales events; no immediate cash flow impact.

deferred revenuemilestone incomeequity investment

Risk Factors

  • Regulatory approvals in China may be delayed or denied, impairing milestone and royalty potential.
  • Equity stake in private Nicoya is illiquid and may never generate realized value.
  • RAYALDEE faces competition from existing vitamin D therapies and SHPT treatments in China.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3284852

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026